|
| Trial, year of publication | | Comparison | LDL reduction | CV event reduction | Adverse events | Comment |
|
| Cannon et al., 2004 | 4162 | PVS versus AVS | - | 26.3% versus 22.4% | 21.4% versus 22.8% | Median LDL level - 62 mg/dl |
|
| TNT, 2005 | 18,003 | AVS 10 mg versus 80 mg | - | 20–30% fewer CV events in AVS 80 mg group | 5.8% versus 8.1% | - |
|
| SPARCL, 2006 | 4731 | AVS versus placebo | - | - | 93% versus 91% | 16% relative reduction in the risk of stroke |
|
| JUPITER, 2008 | 17,802 | RSV versus placebo | 50% lower LDL in RSV group | 20% reduction for each 1 mmol/L decline in LDL level | 15.2% versus 15.5% | Median LDL in RSV group of 55 g/dl at 12 months |
|
| IMPROVE-IT, 2015 | 18,144 | EZE + statin versus statin | EZE lowered LDL-C further by 24% | 7.2% lower risk of major vascular events | No significant difference | Mean LDL level I EZE group of 53.2 mg/dl |
|
| YUKAWA-2, 2016 | 404 | E-mAb versus placebo | 75.9% reduction in E-mAb group | - | 46.5% versus 51% | Median LDL in E-mAb group of 28 g/dl |
|
| Post hoc analysis of 10 ODYSSEY trials, 2016 | 4974 | A-mAb versus placebo, A-mAb versus EZE | −55.4% versus +2.7%
−48.1% versus −18.0% | Every 39 mg/dl fall in LDL was translated into 24% lower risk of MACE | 79.9% versus 81.3%, 76% versus 73.9% | 33.1% of the pooled cohort achieved LDL < 50 mg/dl |
|
| Pooled analysis of 14 randomized trials, 2017 | 5234 | A-mAb versus control (placebo or EZE) | LDL levels reported to be as low as 15 mg/dl in A-mAb group with an increase in adverse event rates | - | Low LDL levels (even <15 mg/dl) were not associated | - |
|
| FOURIER, 2017 | 27,564 | E-mAb versus placebo | 59% reduction as compared to placebo | - | No significant differences except injection site reactions were more common with E-mAb | Rate of CV events was 9.8% versus 11.3% |
|
| ORION-1 (dose ranging trial), 2017 | 501 | Inclisiran versus placebo | 51% reduction with 2 dose regimen | - | 11% versus 8% | 48% subjects attained LDL levels below 50 mg/dl |
|
